HIV Diagnostics Market

The HIV Diagnostics Market is valued at USD 3.4 Bn in 2026 and is projected to reach USD 6.8 Bn, growing at a CAGR of 10% by 2033.

Rapidly Increasing Antibody Test to Fuel Growth of HIV Diagnostics Market

Effective treatment radically reduces infectiousness and prevents the transmission of HIV. Early diagnosis of HIV is therefore a priority, to enable people to access treatment. HIV antibodies are found in blood or saliva by the antibody test. When viruses or bacteria enter the body, the immune system produces antibodies. After 3–12 weeks following infection, a person can find out if they are positive for HIV by taking an antibody test. It may take the immune system a few weeks or more to produce HIV antibodies. With the kits, the patient can test for HIV antibodies privately at home. The dominance in HIV diagnostics market expansion can be ascribed to the effectiveness of antigen testing and the rise in HIV/AIDS prevalence worldwide.

According to a study published in November 2019 titled "Good Practices in the Long-term Care Of People Living with HIV: Learning from Country Experiences Germany and Romania," an estimated 86,000 HIV-positive people live, about 20% of them residing in Berlin. The country's high incidence of HIV increases demand for its diagnostics, propelling the market under study. According to the United Kingdom Health Security Agency report "HIV testing, new HIV diagnoses, outcomes and quality of care for people accessing HIV services: 2021 report," in 2020, an estimated 97,740 people were living with HIV in England, and an estimated 4,660 people were unaware they were infected, indicating that diagnostic services are not offered to the majority of the population. As a result, the nation has enormous potential for market expansion. The development initiatives and programs are also stimulating the world economy. For example, the government released an HIV action plan in December 2021, backed by more than GBP 23 million in financing, to reduce new HIV infections by 80% by 2025 and eliminate diseases and deaths in England by 2030. The HIV diagnostics market will grow by increasing diagnostic capabilities in the nation and aligning investments with strategic objectives. Product introductions also contribute toward HIV diagnostics market expansion.

Efficacy of Treatment Properties of Antibody Testing to Drive Growth of HIV Diagnostics Market

Antibody testing, viral load testing, and CD4 testing are the three test categories used in the HIV diagnostics market. The leading segment will be a viral load test. A lab test called a viral load test is used to assess the patient's body's viral load. These tests improve the efficacy of treatment and produce treatment efficacy in individuals. To track viral load in patients on ART, a high usage of viral load tests is frequently carried out. Modern point-of-care molecular testing allows these tests to be carried out outside laboratories. Segment demand will also be fuelled by a solid product line-up and the presence of major industry players in the sector. For instance, the Cobas plasma separation card for viral load testing was introduced by Roche Diagnostics in 2019. This has improved the company's line of HIV diagnostic products. Thus, several industry changes will encourage the use of viral load assays.

Developed Healthcare Infrastructure to Drive Growth of North America’s HIV Diagnostics Market

North America is the largest user of HIV Diagnostics and is expected to grow at the fastest rate throughout the forecast period. The presence of major companies, the high prevalence of HIV in the area, and the developed healthcare infrastructure are a few of the major factors responsible for the growth of HIV diagnostics market. Approximately 1.2 million Americans have HIV full form is Human Immunodeficiency Virus, resulting in 34,800 new HIV infections in 2019 at a rate of 12.6, according to statistics released by HIV.gov in June 2021 (per 100,000 people). This means that the country has a high incidence of HIV is increasing the demand for its diagnostic tools, which is the market under study.

Additionally, according to a piece by The Borgen Project in October 2021, UNAIDS projected 340,000 HIV-positive individuals in Mexico in 2020, a 55 percent rise from the 230,000 individuals recorded in 2018. Until 2020, the program will help "7,500 at-risk persons in Mexico, Brazil, and Peru" with US$26 Mn in HIV treatment funding. Up to 3,000 patients in Mexico could receive free medicines through the PrEP initiative in Puerto Vallarta, Mexico City, Merida, and Guadalajara. Patients additionally received free condoms, counselling, and STD testing. Therefore, such activities would stimulate market expansion in the area. Additionally, the Global Action in Healthcare Network (GAIHN) and the Global AR Laboratory and Response Network are two new networks created by the Centers for Disease Control and Prevention (CDC) to combat antimicrobial resistance (AR) and infectious diseases (including HIV). Other healthcare threats were each given USD 22 million in December 2021. (Global AR Lab & Response Network). As a result, the market will be driven by rising investments and development of a global network to support diagnostics.

Global HIV Diagnostics Market: Competitive Landscape

The "Afya Kamilifu" project to prevent HIV was begun in the Mara Region in May 2022 by THE Amref Health Africa-Tanzania. The Center for Disease Control and Prevention funds the endeavor (CDC). Undefundsgram, HIV self-test kits were made accessible to all local health facilities. On the other hand, In May 2022, Roche joined with The Global Fund through its Global Access Program to improve HIV diagnosis by strengthening local capacity to address core infrastructural issues about producing and delivering diagnostic results and managing medical waste. This entails creating efficient procedures for gathering, transporting, testing, and returning the results to patients for prompt therapeutic interventions and resolving issues with network infrastructure, workforce capacity, workforce accessibility, and IT systems.

A Few players in the HIV Diagnostics market include

• Abbott Laboratories
• Roche Diagnostics
• Siemens Healthineers
• Danaher Corporation
• Thermo Fisher Scientific
• bioMérieux
• Becton, Dickinson and Company (BD)
• QuidelOrtho Corporation
• Bio-Rad Laboratories
• Hologic, Inc.
• OraSure Technologies
• Alere (Now part of Abbott)
• Fujirebio Inc.
• Sekisui Diagnostics
• LumiraDx

The Global HIV Diagnostics Market Is Segmented as Below:

By Product

• Consumables
• Instruments
• Software & Services

By Test Type

• Antibody Tests
• Viral Load Tests
• CD4 Tests
• Tests for Early Infant Diagnosis
• Tests for Viral Identification

By End User

• Diagnostic Laboratories
• Hospitals
• Blood Banks
• Home Care Settings
• Other

By Region

• North America
• Europe
• Asia Pacific
• LAMEA